The Candidates List: Targets and Possible Therapies for Squamous Cell Carcinoma of the Lung
This article was originally published in RPM Report
The Friends of Cancer Research has identified 16 potential molecular targets and nearly two dozen drugs in development for use in squamous cell carcinoma of the lung. Organizers of a master protocol registrational trial for SCCL hope to select four therapies to test when the study launches in 2014.
You may also be interested in...
Landmark Trial for Personalized Medicine Coming Soon: NGS Approval May Be One Offshoot of Lung Cancer “Master Protocol”
A Friends of Cancer Research/Brookings proposal for a multi-drug, multi-sponsor registrational study of targeted cancer drugs is moving forward. Squamous cell lung cancer will be the initial indication. If successful, the study could lead to rapid final development of several targeted therapies, a potential route to FDA approval of NextGen Sequencing in oncology—and broad adoption of the “master protocol” model.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.